Literature DB >> 12036906

VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells.

Ranjit S Bindra1, James R Vasselli, Robert Stearman, W Marston Linehan, Richard D Klausner.   

Abstract

Renal cell carcinoma is associated with mutation of the von Hippel-Lindau (VHL) tumor suppressor gene. Cell lines derived from these tumors cannot exit the cell cycle when deprived of growth factors, and the ability to exit the cell cycle can be restored by the reintroduction of wild-type protein VHL (pVHL). Here, we report that cyclin D1 is overexpressed and remains inappropriately high in during contact inhibition in pVHL-deficient cell lines. In addition, hypoxia increased the expression of cyclin D1 specifically in pVHL-negative cell lines into which pVHL expression was restored. Hypoxic-induction of cyclin D1 was not observed in other pVHL-positive cell lines. This suggests a model whereby in some kidney cell types, pVHL may regulate a proliferative response to hypoxia, whereas the loss of pVHL leads to constitutively elevated cyclin D1 and abnormal proliferation under normal growth conditions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12036906

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  52 in total

Review 1.  Renal cancer: oxygen meets metabolism.

Authors:  Volker H Haase
Journal:  Exp Cell Res       Date:  2012-03-03       Impact factor: 3.905

2.  pVHL-mediated transcriptional repression of c-Myc by recruitment of histone deacetylases.

Authors:  In-Young Hwang; Jae-Seok Roe; Ja-Hwan Seol; Hwa-Ryeon Kim; Eun-Jung Cho; Hong-Duk Youn
Journal:  Mol Cells       Date:  2012-02       Impact factor: 5.034

3.  Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.

Authors:  Raju R Raval; Kah Weng Lau; Maxine G B Tran; Heidi M Sowter; Stefano J Mandriota; Ji-Liang Li; Christopher W Pugh; Patrick H Maxwell; Adrian L Harris; Peter J Ratcliffe
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

Review 4.  Novel approaches in the therapy of metastatic renal cell carcinoma.

Authors:  John S Lam; John T Leppert; Arie S Belldegrun; Robert A Figlin
Journal:  World J Urol       Date:  2005-04-05       Impact factor: 4.226

5.  Concomitant deregulation of HIF1alpha and cell cycle proteins in VHL-mutated renal cell carcinomas.

Authors:  Derek John Atkins; Christian Gingert; Christina Justenhoven; Gerd Emil Schmahl; Marcellus Stephanus Bonato; Hiltrud Brauch; Stephan Störkel
Journal:  Virchows Arch       Date:  2005-07-01       Impact factor: 4.064

Review 6.  Chemotherapy in metastatic renal cell cancer.

Authors:  Wolfgang Lilleby; Sophie D Fosså
Journal:  World J Urol       Date:  2005-02-22       Impact factor: 4.226

7.  Cyclin D1 genotype and expression in sporadic hemangioblastomas.

Authors:  Johanna M M Gijtenbeek; Sandra H E Boots-Sprenger; Barbara Franke; Pieter Wesseling; Judith W M Jeuken
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

8.  Proline Hydroxylation Primes Protein Kinases for Autophosphorylation and Activation.

Authors:  Sang Bae Lee; Aram Ko; Young Taek Oh; Peiguo Shi; Fulvio D'Angelo; Brulinda Frangaj; Antonius Koller; Emily I Chen; Timothy Cardozo; Antonio Iavarone; Anna Lasorella
Journal:  Mol Cell       Date:  2020-07-07       Impact factor: 17.970

9.  von Hippel-Lindau protein-mediated repression of tumor necrosis factor alpha translation revealed through use of cDNA arrays.

Authors:  Stefanie Galbán; Jinshui Fan; Jennifer L Martindale; Chris Cheadle; Bryan Hoffman; Michael P Woods; Gretchen Temeles; Jürgen Brieger; Jochen Decker; Myriam Gorospe
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

10.  Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.

Authors:  Valentina Bangiyeva; Ava Rosenbloom; Ashlynn E Alexander; Bella Isanova; Timothy Popko; Alan R Schoenfeld
Journal:  BMC Cancer       Date:  2009-07-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.